Theravance Biopharma reaffirms FY23 R&D expense view $35M-$45M

Operating Expenses, excluding share-based compensation and one-time restructuring costs: the Company continues to expect FY23 R&D expense $35M-$45M and SG&A expense $45M-$55M. The Company reaffirms its expectation that it will generate non-GAAP profit in 2H 2023, subject to YUPELRI’s increased net sales growth.